Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Part of paid clinical trials in Fridley, Minnesota.

Sponsor
Incyte Corporation
Study ID
NCT00617994
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Ruxolitinib 1.5% cream BID for 28 days

Study Details

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Key Dates

Start date
Aug 31, 2007
Status verified
Feb 2022
Primary completion
Apr 30, 2009
Completion
May 31, 2009

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group A
    Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
  • Experimental: Group B
    Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
  • Experimental: Group C
    Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.

Primary Outcome Measure

Number of Treatment of Emergent Adverse Events [ Time Frame: Approximately 3 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
-FridleyMinnesota55432-
-RochesterNew York14623-
-AustinTexas78759-
-College StationTexas77840-

Find similar trials in Fridley, MN

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease

Related Studies